episil® oral liquid

[Intended use, Indication]

episil® has a mechanical action indicated for the management of pain and relief of pain, by adhering to the mucosal surface of the mouth, soothing oral lesions including oral mucositis/stomatitis (may be caused by chemotherapy and/or radio therapy).

[Information]

Registration number
22900BZX00214000
JAN code
4987222706476
Approved date
July 6, 2017
Launched date
May 16, 2018
Foreign Manufacturers
Camurus AB (Kingdom of Sweden)
Marketing Authorization Holder
Solasia Pharma K.K. (Japan)
Commercialization and promotion partner
Meiji Seika Pharma Co., Ltd. (Japan)

*”episil®” launched in Japan by its commercialization and promotion partner, Meiji Seika Pharma Co., Ltd..
For more information, please link to Meiji website below; <only available in Japanese>
https://www.meiji-seika-pharma.co.jp/medical/product/episil/

For overseas website, please link to Camurus AB website below;
https://www.episil.net/

Information for use of our products

The site you are about to access is intended to provide information for medical professionals in Japan. It is designed to allow users to better understand Solasia's products.

I have read and understood above

Page Top

SELECT YOUR LANGUAGE